Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.56 - $3.25 $16,536 - $34,450
-10,600 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.61 - $5.2 $17,066 - $55,120
10,600 New
10,600 $34,000

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.